For idiopathic intracranial hypertension (IIH), do nonsteroidal anti-inflammatory drugs (NSAIDs) and/or rimegepant (Nurtec) reduce intracranial pressure and alleviate headaches?

NSAIDs and Nurtec for IIH: Limited Role for Headache Relief, No Effect on Intracranial Pressure

NSAIDs can provide short-term headache relief in newly diagnosed IIH but do not reduce intracranial pressure, while Nurtec (rimegepant) has no established role in IIH treatment and should not be used for this condition.

NSAIDs in IIH

Short-Term Symptomatic Use Only

According to the 2018 consensus guidelines, NSAIDs may be helpful for headache relief only in the first few weeks following IIH diagnosis 1. The guidelines specifically note that indomethacin may have some advantage due to its theoretical effect of reducing ICP, though this remains unproven 1.

Critical Limitations and Warnings

• No ICP reduction: NSAIDs do not address the underlying elevated intracranial pressure that drives IIH 1
• Medication overuse headache risk: You must counsel patients immediately about the danger of using NSAIDs on more than 15 days per month, which can lead to medication overuse headache and worsen their condition 1
• Gastric protection required: Given the potential for prolonged use, gastric protection may be needed 1
• Not a long-term solution: NSAIDs are explicitly recommended only for short-term use during the acute diagnostic phase 1

Nurtec (Rimegepant) in IIH

No Role in IIH Treatment

Nurtec has no established indication or evidence for treating IIH-related headaches or reducing intracranial pressure. The FDA labeling indicates rimegepant is a CGRP receptor antagonist approved for migraine treatment and prevention 2, but there is no mention of IIH in its indications.

Why Nurtec Is Not Appropriate

• Wrong mechanism: Rimegepant works by blocking CGRP receptors, which is effective for migraine pathophysiology but does not address elevated intracranial pressure 2
• No IIH studies: None of the provided evidence discusses rimegepant use in IIH patients
• Different pathophysiology: While 68% of IIH patients have migrainous headache features 1, the underlying driver is raised ICP, not primary migraine pathophysiology

When Migraine Therapies May Be Considered

The guidelines do suggest that if an IIH patient has a clear migrainous headache phenotype AND the papilledema has resolved (IIH in ocular remission), migraine-specific treatments including triptans combined with NSAIDs may be tried 1. However:

• Triptans should be limited to maximum 10 days per month to avoid medication overuse headache 1
• These are most effective when ICP is settling and papilledema has resolved 1
• The 2023 VA/DoD guidelines show rimegepant has only a "neither for nor against" recommendation even for episodic migraine prevention, with a clinically insignificant reduction of 0.8 monthly migraine days 3

The Correct Treatment Approach for IIH

Address the Underlying Elevated ICP

The primary treatment goal must be reducing intracranial pressure, not just treating headache symptoms 1:

1. Weight loss: Most effective intervention for obese patients
2. Acetazolamide: First-line medical therapy (250-500 mg twice daily, titrated up to 4g daily as tolerated) 1
3. Alternative diuretics: Topiramate (25-50 mg twice daily) has dual benefit of carbonic anhydrase activity and appetite suppression 1

Headache-Specific Management Algorithm

For newly diagnosed IIH with active papilledema:

• Short-term NSAIDs or paracetamol for first few weeks only 1
• Warn about medication overuse headache immediately 1
• Start ICP-lowering therapy (acetazolamide or topiramate) 1
• Implement lifestyle modifications (sleep hygiene, regular meals, hydration, stress management) 1

For persistent headache after papilledema resolves:

• Assess headache phenotype carefully 1
• If migrainous features present, consider migraine preventatives (avoiding weight-gaining agents like beta blockers, tricyclics, valproate) 1
• Topiramate may be particularly useful given its dual ICP-lowering and migraine preventative effects 1
• Consider triptan acute therapy (≤10 days/month) combined with NSAID for discrete migraine attacks 1

Common Pitfalls to Avoid

1. Treating headache without addressing ICP: This leaves patients at risk for permanent vision loss 1
2. Allowing medication overuse: Creates refractory headaches that won't respond to preventative treatments 1
3. Using opioids: Explicitly contraindicated in IIH 1
4. Relying on lumbar punctures for headache treatment: Not recommended as therapeutic intervention 1
5. Assuming acetazolamide treats headache directly: It has not been shown effective for headache alone, only for reducing ICP 1

The bottom line: NSAIDs provide only temporary symptomatic relief without addressing the disease process, while Nurtec has no role in IIH management. Focus on ICP reduction through weight loss and carbonic anhydrase inhibitors, with headache-specific therapies reserved for patients with resolved papilledema and persistent migrainous features.